Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans.
Kruti JoshiDominic PilonAditi ShahChristopher HolidaySwapna KarkareMaryia ZhdanavaPublished in: Journal of medical economics (2023)
The majority of patients completed ESK induction phase, and most dosing intervals were longer than the label recommendation. In this descriptive analysis, mental health-related inpatient and ED costs trended lower post-ESK initiation.
Keyphrases